Special Issue

Cystic Fibrosis: Novel Strategies of Diagnosis and Treatments

Message from the Guest Editors

Cystic fibrosis (CF) is the most common fatal genetic disease in Caucasians, with over 2000 known mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR). We are launching a Special Issue entitled “Cystic Fibrosis: Novel Strategies of Diagnosis and Treatments”. The aim of this subject is to highlight the diagnosis and treatment of CF in the era of CFTRm—methods to obtain sputum cultures in patients who do not expectorate sputum after the initiation of CFTRm; effects of CFTRm that have not been studied so far; novel therapies for those ineligible to CFTRm—gene therapy, mRNA therapy; and the diagnosis and treatment of challenging bacteria (such as non-tuberculous mycobacteria—NTM) in patients with and without CFTRm. These topics will help more deeply understand the new face of CF diagnosis and treatments—major advances in the field versus the challenges that remain. Please click *here* to find more information.

Guest Editors

Dr. Michal Gur

1. Pediatric Pulmonary Institute, CF Center, Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa 3109601, Israel
2. Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa 3109601, Israel

Prof. Dr. Lea Bentur

1. Pediatric Pulmonary Institute, CF Center, Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa 3109601, Israel
2. Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa 3109601, Israel

Deadline for manuscript submissions

31 May 2025

Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed

mdpi.com/si/219346

Journal of Clinical Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/jcm

Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed

mdpi.com/journal/jcm

MDPI

About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès
Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi
Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).